Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oyster Point Pharma Inc (OYST)

Oyster Point Pharma Inc (OYST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 299,847
  • Shares Outstanding, K 26,844
  • Annual Sales, $ 24,540 K
  • Annual Income, $ -100,660 K
  • 60-Month Beta 1.35
  • Price/Sales 12.20
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade OYST with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.65
  • Most Recent Earnings $-1.37 on 11/10/22
  • Latest Earnings Date 02/23/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -1.19
  • Number of Estimates 2
  • High Estimate -1.16
  • Low Estimate -1.21
  • Prior Year -1.61
  • Growth Rate Est. (year over year) +26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.04 +1.18%
on 12/23/22
11.25 -0.71%
on 12/01/22
-0.01 (-0.09%)
since 11/30/22
3-Month
5.17 +116.05%
on 10/03/22
11.83 -5.58%
on 11/07/22
+5.55 (+98.75%)
since 09/30/22
52-Week
3.46 +222.83%
on 06/22/22
19.00 -41.21%
on 12/31/21
-7.79 (-41.09%)
since 12/30/21

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, ELVT, LBC, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

IMGO : 36.01 (+0.03%)
ELVT : 1.8700 (+0.54%)
LBC : 9.15 (+0.55%)
OYST : 11.17 (+0.18%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APEN, SAL, LBC, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

APEN : 10.00 (+0.81%)
SAL : 27.88 (+1.57%)
LBC : 9.15 (+0.55%)
OYST : 11.17 (+0.18%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGFS, ATCO, LBC, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AGFS : 3.00 (+0.33%)
ATCO : 15.48 (unch)
LBC : 9.15 (+0.55%)
OYST : 11.17 (+0.18%)
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Oyster Point Pharma, Inc. (NasdaqGS: OYST)...

OYST : 11.17 (+0.18%)
VTRS : 11.34 (+0.80%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OYST, LBC, ELVT, IMGO

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

OYST : 11.17 (+0.18%)
LBC : 9.15 (+0.55%)
ELVT : 1.8700 (+0.54%)
IMGO : 36.01 (+0.03%)
Better Dividend Stock: AbbVie or Viatris?

These pharmaceutical companies are profitable and offer above-average dividends.

PFE : 26.24 (-0.08%)
ABT : 107.79 (+0.67%)
OYST : 11.17 (+0.18%)
ABBV : 169.64 (+1.04%)
VTRS : 11.34 (+0.80%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, USER, AGFS, OYST

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BTRS : 9.49 (-0.11%)
USER : 7.50 (-0.13%)
AGFS : 3.00 (+0.33%)
OYST : 11.17 (+0.18%)
SHAREHOLDER ALERT: Weiss Law Reminds AGTC, OYST, VLDR, and BTRS Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

AGTC : 0.3936 (+1.23%)
OYST : 11.17 (+0.18%)
VLDR : 1.2600 (+0.80%)
BTRS : 9.49 (-0.11%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ABMD, BNFT, OYST, VLDR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

ABMD : 381.02 (+0.06%)
BNFT : 10.50 (+0.10%)
OYST : 11.17 (+0.18%)
VLDR : 1.2600 (+0.80%)
SHAREHOLDER ALERT: Weiss Law Reminds OYST, VLDR, ECOM, and LOTZ Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

OYST : 11.17 (+0.18%)
VLDR : 1.2600 (+0.80%)
ECOM : 23.09 (+0.04%)
LOTZ : 0.1480 (-1.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Oyster Point Pharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The company's lead product candidate, OC-01, is being developed as a nasal spray to treat the signs and...

See More

Key Turning Points

3rd Resistance Point 11.29
2nd Resistance Point 11.24
1st Resistance Point 11.21
Last Price 11.17
1st Support Level 11.13
2nd Support Level 11.08
3rd Support Level 11.05

See More

52-Week High 19.00
Fibonacci 61.8% 13.06
Fibonacci 50% 11.23
Last Price 11.17
Fibonacci 38.2% 9.40
52-Week Low 3.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar